BMJ Open Impact Factor

BMJ Open also carries a CiteScore of 4.5, an SJR of 1.016, and a SNIP of 0.944 in Scopus (2024). These Scopus metrics place the journal in Q1 in broad medicine, which is a notch above its JCR Q2 ranking because the Scopus category is wider.

The COVID-era spike to 4.4 in 2021 was driven by heavily cited pandemic-related research. BMJ Open published a large volume of COVID observational studies, many of which accumulated citations rapidly. The drop back to 2.3-2.4 represents a return to baseline, not a decline in journal quality.

The five-year JIF of 2.7 smooths over that spike and gives a more accurate picture. BMJ Open has been remarkably consistent in the 2.3-2.8 range outside the pandemic years.

In our pre-submission review work with manuscripts targeting BMJ Open, three patterns generate the most consistent desk rejections.

Reporting guideline compliance claimed but not implemented in the text. BMJ Open's author instructions state: "All manuscripts reporting clinical trials should include a CONSORT flow diagram" and "Observational studies should be reported using STROBE guidelines." The journal's transparent peer review model means reviewer comments are published alongside accepted papers, which creates direct accountability for editors who pass through poorly reported manuscripts. The most common desk-rejection trigger: the mandatory reporting checklist PDF is attached but the manuscript text omits required elements. The protocol was not registered before enrollment, the CONSORT flow diagram is missing, or STROBE items like exposure measurement and sample selection are not described in the Methods. BMJ Open editors are stricter about this than many authors expect for a broad-access journal.

Study design that cannot support the stated conclusions. BMJ Open publishes "any study design" but states submissions must be "scientifically valid." The journal's policy guidance explicitly excludes studies with "unacceptable methodology" regardless of findings. Designs that routinely fail this screen: case series without comparative data, cross-sectional surveys with non-probability samples presented as representative, and before-after studies without control groups that draw causal conclusions. The framing issue is that authors who submit these designs often present limitations as minor caveats rather than addressing why the design choice is defensible for the research question. The editorial question is whether a reasonable reader could interpret the results without being misled by the study design.

Insufficient ethics and consent documentation. BMJ Open's author instructions require authors to provide "ethics committee approval and patient consent or waiver" as part of submission. For studies in low and middle income countries or studies involving vulnerable populations, the journal applies additional scrutiny. Manuscripts submitted without a named ethics committee, approval reference number, and consent statement in the Methods section regularly receive desk rejection. "Ethics approval was obtained from the institutional review board" without a committee name, country, and reference number is not sufficient.

A BMJ Open submission readiness check can verify your reporting guideline implementation against BMJ Open's actual checklist requirements and flag ethics documentation gaps before you submit.

BMJ Open accepts all study types across medicine. That's the official scope. In practice, what fills its pages tells you a lot about where your paper fits:

What gets published most frequently:

• Observational cohort and cross-sectional studies
• Systematic reviews and meta-analyses
• Study protocols (yes, they publish protocols before results exist)
• Qualitative research and mixed-methods studies
• Health services research and implementation science
• Public health and epidemiology studies

What's notable about this list: BMJ Open is one of the few indexed, respectable journals that actively welcomes study protocols and qualitative research. Most medical journals treat these as second-class submissions. BMJ Open treats them as legitimate contributions to the literature, and researchers in these areas know it.

What gets desk-rejected:

• Case reports (BMJ Open doesn't publish them; try BMJ Case Reports)
• Laboratory bench science without clinical relevance
• Studies with no ethics approval documentation
• Papers that don't follow reporting guidelines (STROBE, CONSORT, PRISMA)
• Manuscripts where the sample size doesn't support the conclusions

That last point is worth emphasizing. BMJ Open will publish small studies, but only if you're transparent about the limitations. A study with n=30 that claims generalizable results will get rejected. The same study framed as a pilot with appropriate caveats has a real shot.

BMJ Open pioneered fully open peer review in clinical medicine. Here's what that means in practice:

Every accepted paper gets its reviewer reports published alongside it. Not anonymized summaries. The actual reviewer comments, the editor's decision letters, and the authors' point-by-point responses. All of it, publicly accessible.

This has practical consequences for authors:

1. Reviewers write more carefully. Knowing their comments will be public tends to reduce dismissive or lazy reviews.
2. You can read reviews of similar papers. Before submitting, pull up a few accepted BMJ Open papers in your area and read the reviewer reports. You'll see exactly what editors and reviewers focused on.
3. Your revision quality matters publicly. A sloppy revision response will be visible to anyone who reads your paper. Treat it like a public document.

Reviewer names are published by default, though reviewers can opt out. About 60% choose to sign their reviews.

BMJ Open accepts roughly 45-50% of submitted manuscripts. That's relatively generous compared to selective journals, but the desk rejection rate is still meaningful. Papers without ethics documentation, without adherence to reporting guidelines, or with fundamental design flaws get caught early.

Typical timeline:

• Editorial assessment: 1-2 weeks
• Peer review: 4-8 weeks (2 reviewers standard)
• First decision: 6-10 weeks from submission
• Revision turnaround: 4-6 weeks (authors' side)
• Total submission to acceptance: 3-5 months

BMJ Open handles about 8,000-10,000 submissions per year and publishes around 3,500-4,000 papers. The volume means the editorial team is experienced at processing manuscripts efficiently, but it also means reviewers are sometimes stretched thin during peak submission periods (January-March and September-November).

BMJ Open charges $1,839 (GBP 1,600) as its article processing charge. That's mid-range for medical OA journals. For comparison, JAMA Network Open charges $3,000 and PLOS Medicine charges $5,300.

Fee waivers exist for corresponding authors from World Bank-classified low-income countries. Partial waivers can be negotiated for lower-middle-income countries. You need to request the waiver at submission, not after acceptance.

One thing to know: BMJ offers a Read and Publish agreement with many institutions. If your university has an agreement, the APC may be covered entirely. Check with your library before paying out of pocket.

For researchers in health services, public health, and primary care, BMJ Open is a workhorse journal. It's where you build a publication record with solid, rigorous clinical work. Nobody will raise an eyebrow at a BMJ Open publication on a CV. It's BMJ-branded, PubMed-indexed, and peer-reviewed.

For researchers in competitive biomedical fields targeting faculty positions at research-intensive institutions, the 2.3 impact factor may not carry enough weight. That's not a judgment on the journal. It's a reality of how hiring committees read CVs. In that situation, consider PLOS Medicine (IF 9.9) or JAMA Network Open (IF 13.8) if the work supports it.

One thing worth knowing: BMJ Open papers do get cited. The journal's h-index of 237 puts it ahead of many journals with higher impact factors. High-volume journals accumulate citations differently than selective ones, and individual BMJ Open papers regularly exceed 50 or 100 citations when the clinical question resonates.

BMJ Open's 2.3 impact factor is exactly what you'd expect from a high-volume, open access medical journal that publishes across all clinical disciplines. It's not trying to compete with The BMJ on selectivity or prestige. It's filling a different role: a transparent, rigorous, accessible home for clinical research that might otherwise sit in a drawer.

The transparent peer review model, reasonable APC, and genuine openness to study types that other journals won't touch (protocols, qualitative research, negative results) make it a practical option. If the work is sound and you don't need a flashy impact factor, BMJ Open delivers what it promises.

The 2.3 impact factor is the number everyone fixates on. Here's the full picture from the 2024 Journal Citation Reports:

Let's be honest about that JCI. A JCI of 0.71 means the average BMJ Open paper is cited 29% below the global average for its field. That's not great, and it confirms what most researchers already suspect: a typical BMJ Open paper doesn't generate the citation traction of work in more selective journals.

But the 92,316 total citations tell a different story. That's massive volume-driven visibility. BMJ Open publishes 3,776 articles per year, more than almost any other medical journal. Individually, papers may not be heavily cited, but collectively the journal's footprint in medical literature is enormous. If your paper addresses a clinical question that practitioners actually search for, BMJ Open's sheer volume means it'll surface in literature searches.

The 5.0-year cited half-life is typical for clinical medicine, papers stay relevant for about five years before citation rates drop off. Not foundational-research territory, but perfectly aligned with the kind of applied clinical work BMJ Open publishes.

The answer depends on your career stage and what kind of paper you're submitting. Here's the practical breakdown:

Early-career researchers in public health, primary care, or health services research should treat BMJ Open as a reliable workhorse. It builds your PubMed-indexed publication record without the 90%+ rejection rates of top-tier journals. That matters when you need publications for your next contract renewal.

Mid-career researchers should use BMJ Open strategically for protocol registrations and secondary analyses from larger studies. Your RCT goes to BMJ or Lancet; the protocol and your sub-group analyses go to BMJ Open. That's not gaming the system, it's placing each paper where it fits best.

Senior researchers often publish in BMJ Open when they want maximum open-access visibility for public health or implementation science work. At that career stage, the IF doesn't matter, the readership does.

A BMJ Open vs. selective venue scope and fit check can help you figure out whether your paper is competitive at a more selective venue or well-matched to BMJ Open.

BMJ Open's Scopus profile tells a slightly different story than the JCR impact factor alone. Its CiteScore of 4.5 captures four years of citation data rather than two, which smooths out annual fluctuations. The SJR of 1.016 weights citations by the prestige of the citing journal, so BMJ Open isn't just cited often, it's cited by credible sources. The SNIP of 0.944 indicates the journal's field-normalized impact is roughly at par for broad medicine. Together, these metrics confirm that BMJ Open's reach is real, even if the 2.3 JIF doesn't look flashy on its own.

Target if:

• The journal's scope matches your paper's primary contribution
• The IF reflects the readership you want to reach
• Your paper can compete at this selectivity level

Consider alternatives if:

• A journal with better scope fit exists even if the IF is lower
• The IF is the primary reason you're considering this journal
• A specialist society journal would give your paper stronger recognition